ProductoActualizado el 30 de abril de 2026
RADIOPATH: A patient-specific 3D-printed system enabling accurate alignment between radiological imaging and histopathological analysis of tumor samples.
Head of Technology Transfer Office en ISTITUTO EUROPEO DI ONCOLOGIA SRL
Acerca de
The use of radiological imaging to extract quantitative features for the noninvasive characterization of tumors is gaining increasing attention, yet whole histopathological analysis based on tissue biopsy or surgical resection remains the diagnostic gold standard. To validate radiologic features and ensure reliable correlation between imaging and tissue-based observations, accurate spatial alignment between radiologic and histologic data is essential. In this context, 3D printing has emerged as a transformative technology that supports clinicians by enabling the production of cost-effective, patient-specific medical devices that can aid in specimen analysis.
Our device is a patient-specific 3D-printed system that ensures accurate alignment between radiological imaging and histopathological analysis. Created from pre-surgical scans and tumor segmentation, it features a dedicated mold and cutting guides to preserve specimen orientation and ensure radiological–histological correlation. This consistency improves reproducibility and enhances diagnostic confidence.
Advantages:
- Patient-specific 3D-printed mold
- Accurate positioning of the pathological specimen.
- Standardization of gross cutting procedures.
- Adaptability to different solid tumors.
- Compatibility with radiological imaging scanners.
- Possibility of pathological specimen fixation directly inside the mold.
- Possibility of radiological-histological correlation.
IP rights:
IP Asset: patent application IT102025000026158
Owners: IEO, Politecnico di Milano and University of Milan
Archivos adjuntos
Oportunidades similares
Producto
PETsign - A PET-surrogate multigene signature for breast cancer prognosis
Marzia Fumagalli
Head of Technology Transfer Office en ISTITUTO EUROPEO DI ONCOLOGIA SRL
Producto
iRASP: a novel platform to design efficacious cancer targeted immunotherapies
Marzia Fumagalli
Head of Technology Transfer Office en ISTITUTO EUROPEO DI ONCOLOGIA SRL
Producto
NovaRNA - InNOVAtive approach to optimize untraslated regions for next-generation mRNA vaccines.
Marzia Fumagalli
Head of Technology Transfer Office en ISTITUTO EUROPEO DI ONCOLOGIA SRL